Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Genitourinary tumours, non-prostate

905PD - Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder cancer (MIBC)

Date

29 Sep 2019

Session

Poster Discussion – Genitourinary tumours, non-prostate

Topics

Tumour Site

Urothelial Cancer

Presenters

Andrea Necchi

Citation

Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

Authors

A. Necchi1, R. Madison2, J. Chung3, D. Raggi1, A. Briganti4, F. Montorsi4, J.L. Boormans5, Y. Liu6, J.J. de Jong7, J. Chung3, P.C. Black8, J.S. Ross9, S.M. Ali3, E. Davicioni10, E.A. Gibb11

Author affiliations

  • 1 Medical Oncology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 2 Clinical Bioinformatics Operations, Foundation Medicine, 02141 - Cambridge/US
  • 3 Clinical Development, Foundation Medicine, 02141 - Cambridge/US
  • 4 Urology, IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 5 Urology, Erasmus MC Cancer Center, 3075EA - Rotterdam/NL
  • 6 Computational Bioscience, Decipher Biosciences, 1152 - Vancouver/CA
  • 7 Urology, Erasmus MC Cancer Institute, 3015 - Rotterdam/NL
  • 8 Urologic Sciences, Vancouver Prostate Centre, V6H 3Z6 - Vancouver/CA
  • 9 Pathology, Foundation Medicine, 02141 - Cambridge/US
  • 10 Chief Scientific Officer, Decipher Biosciences, 1152 - Vancouver/CA
  • 11 Sr. Scientist,bladder Cancer Lead, Decipher Biosciences, 1152 - Vancouver/CA

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 905PD

Background

In PURE01 study (NCT02736266), neoadjuvant pembro resulted in 42% pT0 in patients (pts) with MIBC. pT0 pts had features suggesting pre-existing immunity or higher tumor mutational burden (TMB) may promote response. In this study, we investigated potential mechanisms for resistance to pembro, including FGFR3 genomic alterations (GA).

Methods

Pts enrolled in the PURE-01, which is still recruiting pts in its amended design, had predominant urothelial carcinoma histology and stage cT ≤ 4N0 MIBC. Biomarker analyses in the expanded cohort of 96 pts included PD-L1 combined positive score and comprehensive genomic profiling (FoundationCDx assay). In addition, TCGA MIBC (n = 405) and a prospective commercial cohort (PCC) of 415 MIBC pts from the clinical use of the Decipher Bladder TURB test from the GRID registry (NCT02609269) were analyzed. A single-sample genomic classifier (GC) was trained to identify FGFR3-active tumors (FGFR3+).

Results

In PURE01 cohort, despite a linear association of TMB with ypT0 in multivariable models (p = 0.017), there was no association between FGFR3 GA and pathological response nor with PD-L1 expression. FGFR3 GA were found in 17.6% ypT0 vs 20.7% in ypT3-4 disease (corrected p = 0.82). Applying the GC to the TCGA MIBC cohort, we found 45% of FGFR3+ cases had FGFR3 mutations vs 9% for the rest of the cohort. Applying the GC to the PCC, we found that the FGFR3+ tumors were Luminal (n = 14), Luminal Infiltrated (n = 10) or Luminal Papillary (n = 30). FGFR3+ pts showed significantly lower PD-L1 (-0.03 vs. 0.109, p < 0.001) and PD-L2 (0.184 vs. 0.389, p < 0.001), but consistent PD-1 (0.175 vs. 0.163, p = 0.48) gene expression. FGFR3+ pts had lower immune and stromal infiltration as measured by the immune190 (0.227 vs. 0.348, p < 0.001) and Estimate (100.14 vs. 1099.2, p < 0.001) gene expression signatures.

Conclusions

In our combined cohorts, FGFR3 GA did not correlate with response to pembro. FGFR3 GA are enriched in FGFR3+ tumors, which in turn tend to have lower immune activity, PD-L1 and PD-L2, suggesting FGFR3 activity may provide a potential tool for further discriminating the mechanisms underlying response and resistance to neoadjuvant pembro in MIBC.

Clinical trial identification

NCT02736266 (PURE01) NCT02609269 (GRID Registry).

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Decipher Bioscience.

Disclosure

A. Necchi: Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (institution), Advisory / Consultancy: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BMS; Advisory / Consultancy, Research grant / Funding (institution): Incyte; Advisory / Consultancy: Clovis; Advisory / Consultancy: Janssen. R. Madison: Full / Part-time employment: Foundation Medicine. J. Chung: Full / Part-time employment: Foundation Medicine. Y. Liu: Full / Part-time employment: Decipher Bioscience. J. Chung: Full / Part-time employment: Foundation Medicine. J.S. Ross: Full / Part-time employment: Foundation Medicine. S.M. Ali: Full / Part-time employment: Foundation Medicine. E. Davicioni: Full / Part-time employment: Decipher Bioscience. E.A. Gibb: Full / Part-time employment: Decipher Bioscience. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.